Ye, D., Dai, B., Gu, W., Jiang, S., Luo, H., Zhou, F., He, D., Ma, L., Guo, H., Liang, C., Chong, T., Zhang, J., Chen, Z., Wang, Y., Zou, Q., Tian, Y., Xiao, J., Yang, X., Lian, J., Wang, W. (2026). Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5090